Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event

Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it will participate in a Virtual Investor Closing Bell event on Tuesday, July 14, 2026, at 4:00 PM ET.

For the segment, Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, will provide a brief corporate overview highlighting the recent launch of FloraSync LF5™, the Company's strategy for thoughtfully building its commercial business while advancing its differentiated women's health pipeline, and the milestones that will shape Daré's long-term growth.

The discussion will also provide insight into the Company's disciplined approach to capital allocation, commercialization, and execution as it works to create sustainable value for shareholders.

Additionally, there will be a live question and answer session with audience participants. Ms. Martucci Johnson will answer as many questions as possible in the time allowed.

A live video webcast will be available on the Presentations, Events & Webcasts page of the Investors section of the Company’s website ( darebioscience.com ). A webcast replay will become available approximately two hours following the live event and will be accessible in the same section of the Company’s website for 90 days.

ABOUT DARÉ BIOSCIENCE, INC. Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation...